Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells.
Stress signaling etches heritable marks on chromatin.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
First NW patient to receive OHSU/VAMC-invented MS drug
Time limited immunomodulatory functions of transplanted neural precursor cells.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Epigenetic changes in patients with multiple sclerosis.
Multiple sclerosis and progressive resistance training: a systematic review.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
[Multiple sclerosis : actuality and therapeutic prospects].
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent

Pages